ANTX Stock Summary and Trading Ideas (An2 Therapeutics | NASDAQ:ANTX)

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

An2 Therapeutics trades on the NASDAQ stock market under the symbol ANTX.

As of October 17, 2024, ANTX stock price declined to $1.03 with 286,878 million shares trading.

ANTX has a beta of 2.41, meaning it tends to be more sensitive to market movements. ANTX has a correlation of 0.02 to the broad based SPY ETF.

ANTX has a market cap of $30.72 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that ANTX belongs to (by Net Assets): VTI, VXF, IWC.

ANTX has underperformed the market in the last year with a price return of -93.1% while the SPY ETF gained +35.2%. ANTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -62.1% and -1.9%, respectively, while the SPY returned +3.4% and +2.4%, respectively.

ANTX support price is $1.03 and resistance is $1.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANTX shares will trade within this expected range on the day.